Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system

In real-world pharmacovigilance studies, the peripheral neurotoxicity of carfilzomib and ixazomib was lower than that of bortezomib. In addition to PN, it is necessary to pay more attention to the special central neurological adverse events of PIs, such as posterior reversible encephalopathy syndrome (PRES) related to bortezomib and carfilzomib, and hypertensive encephalopathy related to carfilzomib, for early symptom identification and diagnosis. For ixazomib, attention should also be paid to neuromuscular symptoms and prevention of neuralgia caused by herpes zoster virus.